Clinical Data ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term Pharmaceutical TechnologyAt ECO 2026, data from the SURMOUNT-MAINTAIN trial evaluating the use of Eli Lilly's Zepbound (tirzepatide) in sustaining weight loss was presented.Metabolic & GLP-1Read full story pharminent May 15, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology At ECO 2026, data from the SURMOUNT-MAINTAIN trial evaluating the use of Eli Lilly’s Zepbound (tirzepatide) in sustaining weight loss was presented. Metabolic & GLP-1 Read full story Post navigation Previous: Trial miss doesn’t dent Biogen’s faith in Alzheimer’s drugNext: Kyowa Kirin secures FDA approval for Crysvita dosing update Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
